Dr. Breitmeyer is a Harvard and Washington University trained, Board certified Medical Oncologist and Immunologist with over 30 years of experience in the pharmaceutical industry. He joined Oncternal in September 2015, when the company was known as Tokalas, Inc. He previously served as President of Bavarian Nordic, Inc. and Executive Vice President of Bavarian Nordic A/S where he was responsible for the successful licensing of an oncology asset to Bristol Myers Squibb for $975M. He currently serves as a director on the board of public biotech companies Zogenix, Inc. (ZGNX) and Otonomy, Inc. (OTIC). Dr. Breitmeyer held executive leadership positions at Zogenix Inc., Cadence Pharmaceuticals, Inc. (acquired by Mallinkrodt), Applied Molecular Evolution (acquired by Eli Lilly and Company), Serono Laboratories (acquired by Merck KGaA), and was the founding President and CEO of the Harvard Clinical Research Institute. He has led efforts resulting in eight FDA and/or international product approvals including Zohydro®, Ofirmev®, Rebif®, Saizen®, Geref®, Serostim®, Fertinex®, and Gonal-F®.